iwCLL 2023

ISS (Industry Satellite Symposia)

Saturday, October 7, 2023

12:55 PM – 1:55 PM

Hynes Convention Center, Ballroom ABC, Level 3

Choosing Wisely, Achieving Control with BTKi Inhibitors in CLL: Expert Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy
Chair & Presenter:
John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

Daniel Addison, MD
The Ohio State University
Columbus, Ohio

Matthew S. Davids, MD, MMSc
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Jennifer Woyach, MD
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele
IRCCS Ospedale San Raffaele
Milano, Italy

This activity is supported by an independent educational grant from AstraZeneca.

Sunday, October 8, 2023

10:20 AM – 11:20 AM
Hynes Convention Center, Ballroom ABC, Level 3
Chronic Lymphocytic Leukemia: Applying the Latest Evidence with BTK Inhibitors to Clinical Decision-Making

Moderator:
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts, United States 

Panelists:
Barbara F. Eichhorst, MD
Associate Professor
Consultant Hematologist
Co-Chair of GLLSG
Department for Internal Medicine
University Hospital of Cologne
Cologne, Germany

Deborah Stephens, DO
Assistant Professor
Director of the CLL and Richter’s Program
Lineberger Comprehensive Cancer Center
at University of North Carolina Chapel Hill
Chapel Hill, North Carolina, United States

This activity is supported by an independent educational grant from BeiGene.
1:45 PM – 2:45 PM
Hynes Convention Center, MR 302, Level 3
Partnerships in CLL: Evolving Patient Goals and Treatment Considerations

Presenters/Moderators:
John Seymour, MBBS, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia

Carolyn Owen, MD, FRCPC
University of Calgary
Calgary, Alberta, Canada

Matthew Davids, MD, MMSc
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

An industry supported symposium provided by AbbVie.

Monday, October 9, 2023

11:35 AM – 12:35 PM
Hynes Convention Center, MR 302, Level 3
Ibrutinib for the Frontline Management of Patients with Chronic Lymphocytic Leukemia (CLL)

Chair:
Paolo Ghia, MD, PhD
Professor of Medical Oncology
Università Vita-Salute San Raffaele
Milan, Italy

Michael Choi, MD
Associate Clinical Professor
UCSD Moores Cancer Center
San Diego, California, USA

Nakhle Saba, MD
Assistant Professor of Clinical Medicine
Tulane University
New Orleans, Louisiana, USA

An industry supported symposium provided by Janssen Pharmaceutical Companies of Johnson & Johnson.